Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of TMC435 with peginterferon alfa-2a and ribavirin in previously treated genotype 1 hepatitis C
2009-010590-20Phase 2Completed
- Sponsor
- Tibotec
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of simeprevir in hepatitis C virus infection (7 arms), sponsored by Tibotec. Primary endpoints: Sustained virologic response at 24 weeks after planned end of treatment and Efficacy comparison of TMC435 regimens versus standard of care alone. Started Aug 2009; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-010590-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010590-20.